Byooviz Gains Interchangeability Status
The ranibizumab biosimilar was the first in ophthalmology to the US market in 2022, but its competition has already had a year of interchangeability exclusivity.
Stay updated with breaking news from Regeneron Eylea. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The ranibizumab biosimilar was the first in ophthalmology to the US market in 2022, but its competition has already had a year of interchangeability exclusivity.
Animal studies of a new compound, which can be delivered by eye drop, have found that it can reverse epigenetic changes that lead to wet age-related macular degeneration.
Prestige Biologics, a contract development and manufacturing organization (CDMO), announced it has signed a non-binding MOU with Aurigene…
Read the latest Regeneron headlines - updated 24/7/365. We link to the best sources from around the world. Get the latest on Regeneron...